esketamine also known sketamine sketamine enantiomer dissociative hallucinogen drug used general anesthetic antidepressant treatment depression sold brand names spravato depression ketanest anesthesia among esketamine active enantiomer ketamine terms nmda receptor antagonism potent racemic specifically used therapy treatmentresistant depression trd major depressive disorder mdd cooccurring suicidal ideation effectiveness depression modest similar esketamine used infusion vein anesthesia fda approved depression form intranasal spray parent compound ketamine often administered intravenously direct medical supervision nasal adverse effects esketamine include dissociation dizziness sedation nausea vomiting vertigo numbness anxiety lethargy increased blood pressure feelings less often esketamine cause bladder esketamine acts primarily nmethyldaspartate nmda receptor antagonist also form racemic ketamine esketamine first synthesized introduced medical use anesthetic enantiopure esketamine introduced medical use anesthetic antidepressant used anesthetic european union antidepressant united states due misuse liability dissociative hallucinogen esketamine controlled esketamine used similar indications uses include induction anesthesia highrisk patients circulatory shock severe bronchospasm supplement regional anesthesia incomplete nerve esketamine approved brand name spravato form nasal spray added conventional antidepressant therapy treatmentresistant depression trd well major depressive disorder mdd associated suicidal ideation behavior adults united clinical trials led approval esketamine trd defined mdd inadequate response least two different conventional nasal spray formulation esketamine used depression delivers two sprays containing total mg esketamine doses mg devices mg devices recommended dosage spravato mg day mg twice per week weeks mg per week weeks mg every weeks weekly week dosing individualized least frequent dosing necessary maintain response spravato administered supervision healthcare provider patients monitored least hours treatment due concerns sedation dissociation misuse esketamine available treatment depression certified providers restricted program risk evaluation mitigation strategy rems called spravato five clinical studies esketamine trd submitted evaluated fda approval esketamine treatment trd sought janssen five studies three shortterm efficacy studies transform two three studies find statistically significant antidepressant effect esketamine relative one positive shortterm efficacy study difference esketamine placebo depression rating scale madrs weeks treatment p scale ranges average score participants start study esketamine placebo total change score weeks points esketamine group points placebo corresponded percentage change madrs score baseline esketamine placebo difference reduction depression score potentially attributable pharmacological action esketamine patient placebo showed antidepressant effect esketamine trd study hence approximately antidepressant response attributable two negative shortterm efficacy trials reach statistical significance differences madrs reductions esketamine placebo p p weeks additional reduction madrs score esketamine placebo single positive efficacy trial corresponds less minimal improvement criticized threshold clinically meaningful difference least points originally suggested trial investigators reasonable threshold clinical literature madrs reductions interpreted much improved corresponding points much improved points minimally improved additionally argued small advantage scores esketamine may related enhanced placebo response esketamine group due functional unblinding caused psychoactive effects words argued study truly doubleblind controlled dissociation experienced side effect majority participants received esketamine esketamine placebo difference severe dissociation experienced deblinding expectancy confounds problems studies hallucinogens psychiatric indications fda normally requires least two positive shortterm efficacy studies approval antidepressants requirement loosened esketamine relapseprevention trial allowed fill place second efficacy trial first time fda known made exception decision criticized lowering regulatory relapseprevention trial rate depression relapse significantly lower esketamine continued discontinued replaced placebo esketaminetreated stable responders remitters rate reduction remitters reduction esketamine approved treatment mdd cooccurring suicidal ideation behavior basis two shortterm phase trials esketamine nasal spray added conventional primary efficacy measure reduction madrs total score hours following first dose trials madrs scores significantly reduced esketamine relative placebo mean madrs scores baseline groups madrs reductions hours esketamine placebo resulting mean differences esketamine placebo secondary efficacy measure trials change clinical global impression suicidal severity revised cgissr hours first dose cgissr singleitem scale scores ranging esketamine significantly effective reducing suicidality relative placebo measure either hours hours cgissr scores changed esketamine placebo giving nonsignificant mean difference esketamine placebo hence efficacious reducing depressive symptoms people depression suicidality antisuicidal effects esketamine individuals expectations initially high ketamine esketamine treatment depression based early smallscale clinical studies discovery rapid ostensibly robust antidepressant effects ketamine described authors important advance field psychiatry past half according review ketamine showed double antidepressant effect size placebo conventional antidepressants treatment depression based preliminary evidence available time cohens ketamine cohens midazolam active placebo cohens conventional however efficacy ketamineesketamine depression declined dramatically studies became larger methodologically effectiveness esketamine indication trd described modest similar magnitude antidepressants treatment comparative effectiveness ketamine esketamine treatment depression adequately january metaanalysis reported ketamine similarly effective esketamine terms antidepressant effect size smdtooltip standardized mean difference depression score vs effective esketamine terms response remission rates rrtooltip risk ratio vs rr response rr vs rr september cochrane review found ketamine effect size smd depression hours low certainty esketamine effect size smd hours based moderatecertainty however metaanalyses involved largely nondirectly comparative studies dissimilar research designs patient single clinical trial directly compared ketamine esketamine depression may study reported similar antidepressant efficacy well tolerability psychotomimetic effects two however study small underpowered research still needed bettercharacterize comparative antidepressant effects ketamine preliminary research suggests arketamine enantiomer ketamine may also independent antidepressant effects may contribute antidepressant efficacy racemic ketamine research likewise needed evaluate february outside panel experts recommended vote fda approve nasal spray version esketamine trd provided given clinical setting people remaining site least two hours reasoning requirement trial participants temporarily experienced sedation visual disturbances trouble speaking confusion numbness feelings dizziness immediately approval esketamine trd fda controversial due limited mixed evidence efficacy january esketamine rejected national health service nhs great nhs questioned benefits medication depression claimed people already using esketamine allowed complete treatment doctors considered spravato debuted cost treatment per year launched united states march institute clinical economic review icer evaluates cost effectiveness drugs analogously national institute health care excellence nice united kingdom declined recommend esketamine depression due steep cost modest efficacy deeming sufficiently esketamine second drug approved trd fda following olanzapinefluoxetine symbyax agents like atypical antipsychotics aripiprazole abilify quetiapine seroquel approved use adjunctive therapy mdd people partial response metaanalysis conducted internally fda evaluation esketamine trd fda reported standardized mean difference smd esketamine trd using three phase shortterm efficacy trials conducted similar smd olanzapinefluoxetine trd lower smds aripiprazole quetiapine adjuncts drugs less expensive esketamine may serve affordable alternatives depression similar common adverse effects esketamine depression incidence include dissociation dizziness sedation nausea vomiting vertigo numbness anxiety lethargy increased blood pressure feelings longterm use esketamine associated bladder esketamine approximately twice potent anesthetic racemic mice rapid antidepressant effect arketamine greater lasted longer usefulness arketamine esketamine supported esketamine inhibits dopamine transporters eight times increases dopamine activity brain doses causing intensity effects esketamine generally considered pleasant patients also generally recover mental function quickly treated pure esketamine may result fact cleared system however contradiction arketamine devoid psychotomimetic side unlike arketamine esketamine bind significantly sigma receptors esketamine increases glucose metabolism frontal cortex arketamine decreases glucose metabolism brain difference may responsible fact esketamine generally dissociative hallucinogenic effect arketamine reportedly however another study found difference racemic ketamine esketamine patients level interpretation finding complicated fact racemic ketamine esketamine eliminated human body quickly arketamine racemic ketamine although arketamine slows elimination esketamine introduced medical use anesthetic germany subsequently marketed addition anesthetic effects medication showed properties rapidacting antidepressant subsequently investigated use esketamine received breakthrough designation fdatooltip food drug administration treatmentresistant depression trd major depressive disorder mdd accompanying suicidal ideation november completed phase iii clinical trials treatmentresistant depression united johnson johnson filed food drug administration fda new drug application nda approval september application endorsed fda advisory panel february march fda approved esketamine conjunction oral antidepressant treatment depression august approved us food drug administration fda added indication shortterm treatment suicidal since closely associated ketamine used club drug also known special k tripinducing side esketamine generic name drug inntooltip international nonproprietary name bantooltip british approved name esketamine hydrochloride banmtooltip british approved name also known sketamine sketamine ketamine well developmental code name esketamine sold brand name spravato use antidepressant brand names eskesia ketanest ketanest ketanests ketas use anesthetic veterinary among esketamine schedule iii controlled substance united httpsenwikipediaorgwikiesketamine